In this way, several agents with the ability to inhibit VEGF (e.g., bevacizumab and aflibercept) or its receptors (e.g., cediranib, sunitinib, sorafenib, vatalanib, vandetanib, cabozantinib, and ramucirumab) have been evaluated for glioma therapy [57,66]. This evidence concerns the gene VEGFA and glioma.